Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 33c
November 7, 2017 4:30 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $3.22, $0.33 better than the analyst estimate of $2.89. Revenue for the quarter came in at $412 million versus the consensus estimate of $421 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2017 EPS of $10.70-$11.20, versus the consensus of $10.90.... More
